<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>sinovacexh99_2.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE, 11.25.04
<TEXT>


EXHIBIT 99.2
------------



                              SINOVAC BIOTECH LTD.
                              --------------------
              RECEIVES APPROVAL FOR AMERICAN STOCK EXCHANGE LISTING
              -----------------------------------------------------


BEIJING,  November 25, 2004 - Sinovac Biotech Ltd.  ("Sinovac")  ("the Company")
(NASD  OTC-BB:  SNVBF)  today  announced  that the American  Stock  Exchange has
approved  Sinovac's  application for the listing of the Company's  common stock.
This approval is contingent upon Sinovac being in compliance with all applicable
listing  standards  on the date it begins  trading on the  Exchange,  and may be
rescinded if the Company is not in compliance with such standards. Shares of the
Company's  common  stock are  expected to begin  trading on the  American  Stock
Exchange under the symbol "SVA" within 10 to 15 business days.




About Sinovac Biotech Ltd.
--------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
hepatitis A and hepatitis B, influenza, "SARS", and avian flu. Sinovac is one of
the leading  emerging  biotechnology  companies in China.  Working  closely with
Chinese public health officials,  Sinovac focuses on manufacturing and marketing
human-use  vaccines and related products,  and currently markets its vaccine for
hepatitis A. Sinovac is the first and currently the only company in the world to
have commenced clinical trials for a vaccine to prevent SARS.


Contact:   Investor   Relations   at  (888)  888  8312  or  (604)   684-5990  or
info@sinovac.com
----------------




THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.




</TEXT>
</DOCUMENT>
